Effects of dasatinib treatment on leukocytes

Dasatinib (Dasatinib) is a highly effective kinase inhibitor that is widely used to treat Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). In these diseases, abnormal BCR-ABL proteins cause the bone marrow to overproduce impaired white blood cells that not only fail to perform normal functions but also interfere with the production of normal blood cells, such as red blood cells and platelets.

The therapeutic mechanism of dasatinib works by inhibiting this abnormalBCR-ABL protein. It helps reduce the number of abnormally functioning white blood cells in the body, thereby making room for the production of normal blood cells. This process is achieved by blocking signaling pathways for leukemia cell proliferation and survival, helping to relieve leukemia symptoms and control disease progression.

Dasatinib may affect blood cell counts during treatment. Specifically, it may cause a low red blood cell count (i.e., anemia), a low white blood cell count (neutropenia), and a low platelet count (thrombocytopenia). These changes require close monitoring during treatment to ensure the effectiveness and safety of the treatment.

Doctors typically monitor patients' blood counts regularly and adjust treatment as needed. If the number of white blood cells drops too much or reaches dangerous levels, doctors may respond with a range of measures, including adjusting the dose of the drug, suspending treatment for a period of time, or using other medications to support blood cell production. In addition, patients should also pay attention to self-care during treatment with dasatinib. This includes maintaining good eating habits, avoiding exposure to infections, and engaging in moderate exercise.